No Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis or Those with Severe Chronic Kidney Disease

Abstract

HomeRadiologyVol. 287, No. 1 PreviousNext CommunicationsFree AccessNotice of WithdrawalNo Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis or Those with Severe Chronic Kidney DiseaseMartin DR, Kalb B, Mittal AJ, Salman K, Vedantham S, Mittal PKMartin DR, Kalb B, Mittal AJ, Salman K, Vedantham S, Mittal PKMartin DRKalb BMittal AJSalman KVedantham SMittal PKPublished Online:Mar 20 2018https://doi.org/10.1148/radiol.2018184004MoreSectionsPDF ToolsImage ViewerAdd to favoritesCiteTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinked In Martin DR, Kalb B, Mittal AJ, Salman K, Vedantham S, Mittal PK. No Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis or Those with Severe Chronic Kidney Disease. Radiology 2018:286(1):113–119. https://doi.org/10.1148/radiol.2017170102The authors have requested to withdraw the above manuscript from publication because the study was not conducted in full accordance with the relevant institutional IRB protocol.The companion editorial has also been withdrawn from publication by the authors, in conjunction with the withdrawal of the highlighted manuscript: Prince MR, Weinreb JC. MR imaging and gadolinium: reassessing the risk of nephrogenic systemic fibrosis in patients with severe renal disease. Radiology 2018:286(1):120–121. https://doi.org/10.1148/radiol.2017172255Article HistoryPublished online: Mar 20 2018Published in print: Apr 2018 FiguresReferencesRelatedDetailsAccompanying This ArticleNotice of Withdrawal: No Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis or Those with Severe Chronic Kidney DiseaseFeb 14 2010RadiologyNotice of Withdrawal: MR Imaging and Gadolinium: Reassessing the Risk of Nephrogenic Systemic Fibrosis in Patients with Severe Renal DiseaseFeb 14 2018RadiologyRecommended Articles Notice of Withdrawal: No Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis or Those with Severe Chronic Kidney DiseaseRadiology2010Volume: 286Issue: 1Adverse Events to the Gadolinium-based Contrast Agent Gadoxetic Acid: Systematic Review and Meta-AnalysisRadiology2020Volume: 297Issue: 3pp. 565-572Signal Intensity Changes at MRI Following GBCA Exposure: Incidental Finding or Cause for Concern?Radiology2020Volume: 296Issue: 1pp. 131-133Notice of Withdrawal: MR Imaging and Gadolinium: Reassessing the Risk of Nephrogenic Systemic Fibrosis in Patients with Severe Renal DiseaseRadiology2018Volume: 286Issue: 1Comparison of Human Tissue Gadolinium Retention and Elimination between Gadoteridol and GadobenateRadiology2021Volume: 300Issue: 3pp. 559-569See More RSNA Education Exhibits Practical Approaches and Updated Topics in Gadoxetate-Enhanced MR Imaging of the Liver: What the Radiologists Should KnowDigital Posters2019Gadolinium Deposition and NSF: Should I Be Worried?Digital Posters20182019 MRI Safety Updates for Radiologists: Are We Too Careful or Careless?Digital Posters2019 RSNA Case Collection Autosomal recessive polycystic kidney diseaseRSNA Case Collection2021Brown tumour of the hard palateRSNA Case Collection2020Chronic myocardial infarctionRSNA Case Collection2020 Vol. 287, No. 1 Metrics Altmetric Score PDF download